NL-OMON36095已完成不适用
A phase 0 validation study in healthy male volunteers assessing the safety and tolerability of serial CSF sampling and to evaluate biomarkers related to Alzheimer*s disease in CSF and plasma - serial CSF sampling study
QPS Netherlands B.V.0 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy men
- •BMI 20-27 kg/m2
排除标准
- •Any clinical significant abnormalities
研究者
相似试验
已完成
1 期
A phase I study to determine the tolerability and safety of transdermally delivered oxycodone in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM).To promote pain relief in healthy volunteers.Anaesthesiology - Pain managementACTRN12609000836235Phosphagenics Limited44
已完成
1 期
A Trial in Healthy Participants to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRAX-944Essential TremorNeurological - Other neurological disordersACTRN12620000675921Praxis Precision Medicines24
已完成
不适用
A phase 1 study in healthy volunteers to determine the dermatopharmacokinetics of topically applied diclofenac in combination with the novel penetration enhancer Tocopheryl Phosphate Mixture (TPM), compared with Votaren(registered trademark) gelMuscular or joint pain relief in healthy volunteers currently experiencing no painOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12609000505202Phosphagenics Limited24
终止
1 期
Pharmacokinetic investigation aimed to demonstrate that the new liquid formulation containing (fos)netupitant and palonosetron is similar to the lyophilized (freeze-dried) formulatioChemotherapy-induced nausea and vomitingCancerISRCTN46099817Helsinn (Switzerland)64
进行中（未招募）
1 期
A study in healthy participants to find out how posaconazole interacts with 125mg rilematovir (taken once or twice a day), when they are given together and to find out how long rilematovir stays and acts in the body (pharmacokinetics) when given as 250mg twice a dayEUCTR2020-004050-30-BEJanssen-Cilag International NV45